RNA - NASDAQ

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.

RNAยทNASDAQ

$12.17

-1.3%
HealthcareBiotechnology

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$208.18M
EPS-4.4800
P/E Ratio-2.72
Earnings Date09/02/2026
Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. Fair Value Envelope

RNA ยท NASDAQ

Our analysis suggests that RNA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $12.17, this represents a potential HIDDEN relative to our calculated worth for Atrium Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $12.17

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$22.8B
+ Cash & Equivalents$270.0M
Firm Value-$22.5B
- Debt$3.7M
Equity Value-$22.5B
/ Shares Outstanding131,245,283B
DCF Value-$171
OVERVALUED BY 1508%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$76.6M
-$142.6M
-$265.4M
-$494.1M
-$919.9M
-$1.7B
-$3.2B
-$5.9B
-$11.1B
-$20.6B
Maintenance CapEx
-$538.0K
-$1.0M
-$1.9M
-$3.5M
-$6.5M
-$12.0M
-$22.4M
-$41.7M
-$77.7M
-$144.6M
Owner Earnings
-$77.1M
-$143.6M
-$267.3M
-$497.6M
-$926.4M
-$1.7B
-$3.2B
-$6.0B
-$11.1B
-$20.7B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$71.4M
-$123.1M
-$212.2M
-$365.7M
-$630.5M
-$1.1B
-$1.9B
-$3.2B
-$5.6B
-$9.6B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your RNA research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.